Seeking Alpha's Quant system consistently outperforms the S&P 500 ( SP500 ), driven by powerful computer processing and SA's ...

Eli Lilly has expanded a collaboration with ... against rivals such as Apple and FitBit whose wearable devices have an increasing medical focus with tech like ECG readers. ActiGraph provides ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its ...

After years of preparation, Eli Lilly is on the ... and can link with compatible devices. That includes continuous glucose monitoring systems developed by Lilly's partner Dexcom as well as other ...

Vertex Pharmaceuticals is an innovative powerhouse with a good stock to buy on the dip. You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly's operational performance is strong, but shares are expensive, leading me to reaffirm a 'hold' rating despite potential upside from new drugs. Recent financial results show significant ...

surpassing the Medical sector's loss of 6.22% and falling behind the S&P 500's loss of 1.7%. Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure.

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...